anti- AMPK alpha 1 antibody FNab00375
Background:
The mammalian 5-prime-AMP-activated protein kinase(AMPK) appears to play a role in protecting cells from stresses that cause ATP depletion by switching off ATP-consuming biosynthetic pathways. PRKAA1 is also named as AMPK1, ACACA kinase, HMGCR kinase. It is a mammalian homologue of sucrose non-fermenting protein kinase(SNF-1), which belongs to a serine/threonine protein kinase family. It has 2 isoforms produced by alternative splicing.
Clonality:
polyclonal
Classification:
Primary antibody
Alternative names:
AMPK, AMPK alpha, AMPK alpha 1, AMPK subunit alpha 1, AMPK1, AMPKa1, PRKAA1
Specificity:
Human, Mouse, Rat
Host:
Rabbit
Isotype:
IgG
Immunogen:
protein kinase, AMP-activated, alpha 1 catalytic subunit
Purification:
Immunogen affinity purified
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
63 kDa
Form:
liquid
Applications:
ELISA, WB, IHC, IF
Recommended dilution:
WB: 1:200-1:2000; IHC: 1:100-1:400; IF: 1:10-1:100
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.